Live Webinar
Getting Up To Date: New FDA Psychotropic Medication Approvals in the Last 18 Months
|
Getting Up To Date: New FDA Psychotropic Medication Approvals in the Last 18 Months
1.0 CE Hours
Intermediate
$25 - $35
Pricing
References
References
- Axsome Therapeutics, Inc. (2023, September 13). Addressing dementia via agitation-centered evaluation (ADVANCE) (ClinicalTrials.gov identifier NCT03226522). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03226522?tab=study
- Durgam, S., Earley, W. R., Kozauer, S. G., Chen, C., Lakkis, H., & Cutler, A. J. (2026). Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study. European Neuropsychopharmacology, 108, 112786. https://doi.org/10.1016/j.euroneuro.2026.112786
- Phillips, B., Horta, M., Santini, N., & Chapman, D. (2026). Clinical evaluation of Bysanti: A new atypical antipsychotic for schizophrenia and bipolar I disorder. The Annals of Pharmacotherapy. Advance online publication. https://doi.org/10.1177/10600280261470404